Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated SIACI of Bevacizumab With Temozolomide and Radiation in Newly Diagnosed GBM
NCT05271240Phase 3Recruiting
- Sponsor
- Northwell Health
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in glioblastoma (GBM) (2 arms), sponsored by Northwell Health. Primary endpoint: Overall Survival at 62 months. Started Apr 2022; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05271240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271240.